Home > Healthcare IT > Tuberculosis Drugs Market Size, Growth to 2026
Straits Research

Tuberculosis (TB) Drugs Market

Tuberculosis (TB) Drugs Market: Information by Disease Type (Active TB, Latent TB), Therapy (First-Line, Second-Line), and Region — Forecast till 2026

Table of Content Download Sample

Market Snapshot

market snapshot
Base Year:
2017
Study Period:
2016-2026
CAGR:
6.3 %
Fastest Growing Market:
Asia Pacific
Largest Market:
North America

Tuberculosis is caused by the Mycobacterium tuberculosis bacterium. It spreads when a person with active TB coughs or sneezes and the bacteria come in contact with a healthy person. A weakened immune system is the key cause of tuberculosis prevalence. According to the Central for Diseases Control and Prevention, around one-fourth of the world's population is infected with TB. Further, TB is a vastly prevalent disease among people affected by HIV. According to the Centers for Disease Control and Prevention, in 2017, 10 million people suffered from TB around the globe. Treatments such as biological agents or chemotherapy that weaken the immune system further increases the chances of contracting tuberculosis.

The global tuberculosis drugs market size was valued at around USD 895.5 million in 2017 and is anticipated to exhibit a CAGR of 6.3% during the forecast period. 

Get more information on this report Download Sample Report

Intended Audience

  • Healthcare Institutions
  • Potential Investors
  • Research and Development Institutes
  • Hospitals and Diagnostic Centers

Segmental Insights

The global tuberculosis drugs market can be segmented by disease type and therapy.

On the basis of disease type, the tuberculosis drugs market can be segmented into active TB and latent TB. The active TB segment is expected to dominate the market, due to the increasing incidences of DS and MDR TB cases. Based on therapy, the market can be segmented into first-line therapy and second-line therapy. Among the two, the second line therapy segment is expected to lead the market, owing to rising national surveillance efforts and global initiatives by WHO and Global Drug Facility (GDF).

Regional Analysis

Geographically, the tuberculosis drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (LAMEA).

Tuberculosis Drugs Market Regional Analysis

Regional Growth Insights Request Sample Pages

North America is projected to account for the largest share of the global tuberculosis drugs market during the forecast period, 2019–2026. Increasing prevalence of chronic diseases such as HIV diseases, which weaken the immune system is a key factor providing an impetus to the growth of the tuberculosis drugs market. According to the National Aids Control Organisation (NACO), in 2015, around 1.1 million people suffered from HIV.

Europe is expected to witness significant market growth during the forecast period, owing to the region’s sizable geriatric population. For instance, according to the U.K. Government, in 2017, around 579,776 people were older than 90 years.

Asia-Pacific is pegged to be the fastest growing market during the forecast period according to WHO, South-East Asia Region have the highest population around 45% of total population suffering from tuberculosis. Apart from that 82% of deaths reported among HIV negative people in  South-East Asia Region in 2016. This increasing number of tuberculosis number in Asia-Pacific drives the tuberculosis drugs market.

The LAMEA region is expected to witness substantial market growth during the forecast period, owing to the increasing prevalence of tuberculosis and high disposable income in the Middle East.

Recent Development

  • In September 2018, QIAGEN N.V. and DiaSorin in collaboration launched automated, CE-marked workflow for QIAGEN’s QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) and a novel DiaSorin LIAISON Test which is developed based on immunodiagnostic instruments from DiaSorin. Through this product launch, the company had expanded its product portfolio and Tuberculosis business in Europe.

Key Players

A list of key tuberculosis drugs market suppliers

  • Sigma Pharmaceutical Pty Limited
  • Aventis Pharmaceuticals Limited
  • Novartis AG
  • Sanofi Aventis U.S LLC
  • Hoffmann-La Roche Ltd
  • Akorn
  • Incorporated
  • Bayer Health care.

Report Scope

Report Metric Details
Market Size USD 895.5 million in 2017
CAGR CAGR 6.3%
Historical Data 2015-2016
Base Year 2017
Forecast Period 2018-2026
Forecast Units Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered by Disease Type (Active TB, Latent TB), Therapy (First-Line, Second-Line)
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Sigma Pharmaceutical Pty Limited, Aventis Pharmaceuticals Limited, Novartis AG, Sanofi Aventis U.S LLC, Hoffmann-La Roche Ltd, Akorn, Incorporated, and Bayer Health care.,
Key Market Opportunities The Healthcare It Industry'S Substantial Growth Fuels The Tuberculosis (Tb) Drugs Market

Report Inclusions

  • Historical inferences, findings & analysis of the market for the duration of 2016 to 2018
  • Projections and performance forecast analysis for the duration of 2019 to 2026
  • Production and consumption point-of-view (POV) analysis
  • Market driver, restraint and opportunity analysis to define market dynamics, covering industry, regulatory, innovation, technological & pricing trends
  • Comprehensive competitive landscape mapping with recent developments, covering market leadership, competency, sustainability, and future prospects

Global Tuberculosis Drugs Market: Segmentation

By Disease Type

  • Active TB
  • Latent TB

By Therapy

  • First-Line Therapy
  • Second-Line Therapy

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America and Middle East & Africa

Why Buy This Report?

This report offers key insights pertaining to the TB drugs market with an emphasis on recent developments across geographies and development strategies adopted by prominent market participants. The following sections have specifically been covered in the report.

  • Definitive Market Data
  • Tuberculosis Drug Market Analysis
  • Competitive Analysis
  • Recent Opportunities in the Market
  • 6-7 Year Performance Forecasts: Major Segments by Disease Type, and Therapy.
  • Market Share Analysis
  • Potential Venture Avenues
Price Starts From
USD4250

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report
Want to learn more about recent trends and data ?
They Already Trust Us :
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Johnson & Johnson
Need Assistance?
+1 646 480 7505 (U.S.)
+44 208 068 9665 (U.K.)
Looking For Custom Report ?

Report Benefits

  • Develop business strategies by understanding the trends shaping and driving the Market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track sales in the global and country-specific Market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Check Our License Options :
Report Snapshot

As featured on :

clients
Trusted by Fortune 500
Over 30000+ subscribers